ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Head and neck sarcomas across two decades: a retrospective study of clinicopathologic patterns and oncologic outcomes.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHead and neck sarcomas (HNS) are rare and heterogeneous malignancies with unique anatomical and biological challenges. This study aimed to evaluate clinicopathologic features, treatment approaches, and survival outcomes of bone versus soft tissue HNS, with stratification by grade and anatomical site.
methodsA retrospective review was conducted of 77 consecutive patients with HNS treated at a tertiary referral center between 2000 and 2021. Tumors were classified as bone or soft tissue sarcomas. Clinical characteristics, treatment modalities, and outcomes were analyzed. Survival was estimated using the Kaplan-Meier method and prognostic factors were assessed with Cox proportional hazards models.
resultsNineteen patients (24.7%) had bone sarcomas, which were uniformly high-grade, diagnosed at a younger age, and commonly managed with multimodal therapy. Their 5-year overall survival was 76.0%. Fifty-eight patients (75.3%) had soft tissue sarcomas, with more heterogeneous histology and grade; the 5-year overall survival was 60.4%, and recurrence occurred in 46.6%. Tumors located in the skull base and paranasal sinuses more often had positive margins but did not demonstrate inferior survival compared to other sites. Patients treated with the "sandwich modality" (neoadjuvant therapy, surgery, and adjuvant therapy) showed lower recurrence rates compared with other treatment strategies.
conclusionTumor grade was the most significant prognostic factor in HNS, while histologic type and site also influenced management strategies. The sandwich modality was associated with lower recurrence and warrants further investigation. Individualized, guideline-driven multimodal care remains central to optimizing outcomes in this rare disease.
Indexed as
Identifiers
41329203What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.